Amgen Q3 Revenue Up 8% to $10.4B, Full-Year Guidance Raised to $38.9-39.7B
AMGN sits 58% above its 52-week low of $292.12.
Summary
Amgen posted Q3 2026 revenue of $10.4B, up 8%, and non-GAAP EPS of $6.45, up 14%, then raised full-year revenue guidance to $38.9-39.7B. Offsetting that: biosimilar erosion in Prolia and XGEVA and the pending TAVNEOS withdrawal.
Key Events · Earnings and Guidance · AMGN
-
Q3 Revenue $10.4B, Up 8%
Total revenues rose 8% to $10.4 billion from $9.557 billion, with product sales up 8% to $9.883 billion on volume growth.
-
EPS Growth and Margin Expansion
GAAP EPS rose 19% to $7.08 from $5.93 and non-GAAP EPS rose 14% to $6.45 from $5.64; GAAP operating margin expanded 9.9 points to 37.5%.
-
Full-Year Guidance Raised
2026 revenue guidance was lifted to $38.9-39.7 billion from the $38.2-39.4 billion range given in August; non-GAAP EPS is guided to $22.90-23.70 and GAAP EPS to $18.34-19.28.
-
Biosimilar Erosion Deepens
Prolia sales fell 45% to $632 million and XGEVA fell 47% to $288 million as multiple biosimilars launched globally, partly offsetting growth products Repatha (+37% to $1,085 million) and UPLIZNA (+191% to $451 million).
Analysis · AMGN · Life Sciences
The number that matters for the thesis is the raised guidance: full-year sales are now seen at $38.9-39.7B, up from $38.2-39.4B in August, after the company beat its own revenue outlook, and non-GAAP EPS came in at $6.45, up 14%. Growth products are doing the heavy lifting — Repatha rose 37% to $1,085M, UPLIZNA 191% to $451M and IMDELLTRA 128% to $406M. Against that, biosimilar erosion is steep and accelerating, with Prolia down 45% to $632M and XGEVA down 47% to $288M. TAVNEOS remains under an FDA request to withdraw; a hearing was requested June 1 and supporting materials were submitted July 23. Free cash flow slipped to $3.7B from $4.2B on working capital, and the balance sheet carries $54.0B of debt against $13.2B of cash.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, AMGN was trading at $463.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $249.4B. The 52-week trading range was $292.12 to $475.65. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.